The Role of Mitochondria in HIV Infection and Its Treatment

Journal of Experimental and Clinical Medicine

Volumn 2, Issue 4, 2010, Pages 145-155

  Pinti, Marcello ^a   Nasi, Milena ^a   Gibellini, Lara ^a   Roat, Erika ^a   De Biasi, Sara ^a   Bertoncelli, Linda ^a   Cossarizza, A ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

AIDS; Antiretroviral therapy; HAART; HIV; Mitochondria; Mitochondrial DNA

Indexed keywords

ABACAVIR; ADENOSINE TRIPHOSPHATE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOKINE; DARUNAVIR; DIDANOSINE; EMTRICITABINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; INDINAVIR; LAMIVUDINE; LOPINAVIR; MITOCHONDRIAL DNA; NEF PROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VPR PROTEIN; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; APOPTOSIS; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CELL ENERGY; CELL ORGANELLE; CLINICAL TRIAL; CONFUSION; CYTOPLASM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPLICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG POTENCY; FATIGUE; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LACTIC ACIDOSIS; LIPOATROPHY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MYOPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 77955592746     PISSN: 18783317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1878-3317(10)60024-1     Document Type: Review

References (138)

1. Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, Wiley S, Murphy AN, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol 2003, 21:281-286.
2. Wallace DC The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene 2005, 354:169-180.
3. Kujoth GC, Bradshaw PC, Haroon S, Prolla TA The role of mitochondrial DNA mutations in mammalian aging. PLoS Genet 2007, 3:e24.
4. Pedersen PL The cancer cell's " power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr 2007, 39:1-12.
5. Reichert AS, Neupert W Mitochondriomics or what makes us breathe. Trends Genet 2004, 20:555-562.
6. Kroemer G, Galluzzi L, Brenner C Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
7. Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, Brambilla R, et al. Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 1998, 32:493-504.
8. Ceruti S, Barbieri D, Veronese E, Cattabeni F, Cossarizza A, Giammarioli AM, Malorni W, et al. Different pathways of apoptosis revealed by 2-chloro-adenosine and deoxy-D-ribose in mammalian astroglial cells. J Neurosci Res 1997, 47:372-383.
9. Salvioli S, Dobrucki J, Moretti L, Troiano L, Fernandez MG, Pinti M, Pedrazzi J, et al. Mitochondrial heterogeneity during staurosporine-induced apoptosis in HL60 cells: analysis at the single cell and single organelle level. Cytometry 2000, 40:189-197.
10. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006, 13:1423-1433.
11. Galluzzi L, Larochette N, Zamzami N, Kroemer G Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
12. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985, 82:7096-7100.
13. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
14. Perelson AS, Essunger P, Ho DD Dynamics of HIV-1 and CD4 + lymphocytes in vivo. AIDS 1997, 11(Suppl A):S17-S24.
15. Ho DD Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
16. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
17. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
18. Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000, 181:1635-1642.
19. Mussini C, Pezzotti P, Miro JM, Martinez E, de Quiros JC, Cinque P, Borghi V, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004, 38:565-571.
20. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307.
21. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, et al. Efficacy of shortterm monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170-1172.
22. Hicks C, Gulick RM Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009, 48:931-939.
23. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986, 83:8333-8337.
24. Lynx MD, McKee EE 3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006, 72:239-243.
25. Lynx MD, Bentley AT, McKee EE 3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem Pharmacol 2006, 71:1342-1348.
26. Johnson MA, Fridland A Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol 1989, 36:291-295.
27. Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, Gherardi R, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997, 149:19-25.
28. Setzer B, Schlesier M, Walker UA Effects of of didanosine-related depletion of mtDNA in human T lymphocytes. J Infect Dis 2005, 191:848-855.
29. Balzarini J, Cooney DA, Dalal M, Kang GJ, Cupp JE, DeClercq E, Broder S, et al. 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 1987, 32:798-806.
30. Lee H, Hanes J, Johnson KA Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711-14719.
31. Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, Vray M, et al. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004, 18:181-187.
32. Ho HT, Hitchcock MJ Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989, 33:844-849.
33. Gerschenson M, Nguyen VT, St Claire MC, Harbaugh SW, Harbaugh JW, Proia LA, Poirier MC Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol 2001, 4:335-342.
34. Gaou I, Malliti M, Guimont MC, Letteron P, Demeilliers C, Peytavin G, Degott C, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001, 297:516-523.
35. Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol 2004, 199:10-19.
36. Pinti M, Gibellini L, Guaraldi G, Orlando G, Gant TW, Morselli E, Nasi M, et al. Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipo-dystrophy: implications for the pathogenesis of the disease. AIDS 2010, 24:841-850.
37. Shewach DS, Liotta DC, Schinazi RF Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol 1993, 45:1540-1543.
38. Cui L, Schinazi RF, Gosselin G, Imbach JL, Chu CK, Rando RF, Revankar GR, et al. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem Pharmacol 1996, 52:1577-1584.
39. Venhoff N, Setzer B, Melkaoui K, Walker UA Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007, 12:1075-1085.
40. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 2002, 16:1196-1197.
41. Hawkins T, Veikley W, St Claire RL, Guyer B, Clark N, Kearney BP Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005, 39:406-411.
42. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997, 41:1099-1107.
43. Rylova SN, Mirzaee S, Albertioni F, Eriksson S Expression of deoxynucleoside kinases and 5'-nucleotidases in mouse tissues: implications for mitochondrial toxicity. Biochem Pharmacol 2007, 74:169-175.
44. Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, Unadkat JD Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 2009, 296:G910-G922.
45. Leung GP, Tse CM The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol 2007, 3:705-718.
46. Lai Y, Tse CM, Unadkat JD Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004, 279:4490-4497.
47. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001, 15:1687-1694.
48. Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, Troiano L, Fernandez MG, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active anti-retroviral therapy-related lipodystrophy. J Infect Dis 2002, 185:299-305.
49. Walker UA, Setzer B, Venhoff N Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002, 16:2165-2173.
50. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002, 16:513-518.
51. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002, 29:117-121.
52. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, Martinez E, Soler A, Milinkovic A, et al. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003, 8:333-338.
53. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346:811-820.
54. Lopez S, Miro O, Martinez E, Pedrol E, Rodriguez-Santiago B, Milinkovic A, Soler A, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004, 9:47-55.
55. Maggiolo F, Roat E, Pinti M, Nasi M, Gibellini L, De Biasi S, Airoldi M, et al. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antivir Ther 2010, 15:51-59.
56. Lim SE, Copeland WC Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001, 276:23616-23623.
57. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098-1105.
58. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne RM, Grody WW Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991, 65:228-236.
59. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999, 30:156-160.
60. Kaguni LS DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem 2004, 73:293-320.
61. Lewis W, Day BJ, Copeland WC Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003, 2:812-822.
62. Song S, Pursell ZF, Copeland WC, Longley MJ, Kunkel TA, Mathews CK DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 2005, 102:4990-4995.
63. Chiappini F, Teicher E, Saffroy R, Debuire B, Vittecoq D, Lemoine A Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr HIV Res 2009, 7:244-253.
64. Riddler SA, Anderson RE, Mellors JW Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res 1995, 27:189-203.
65. Rana KZ, Dudley MN Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 1997, 33:276-284.
66. Villalba N, Soriano V, Gomez-Cano M, Castilla J, Mas A, Gonzalez-Lahoz J Short-term efficacy and safety of stavudine in pre-treated HIV-infected patients. Antivir Ther 1997, 2:185-189.
67. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007, 101:793-798.
68. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447-2454.
69. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials 2007, 8:337-344.
70. ter Hofstede HJ, Koopmans PP, Burger DM Stavudine plasma concentrations and lipoatrophy. J Antimicrob Chemother 2008, 61:933-938.
71. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001, 15:1801-1809.
72. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, Jasper J, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 2008, 13:715-722.
73. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15-23.
74. Ribera E, Paradineiro JC, Curran A, Sauleda S, Garcia-Arumi E, Castella E, Puiggros C, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008, 9:407-417.
75. Pedrol E, Masanes F, Fernandez-Sola J, Cofan M, Casademont J, Grau JM, Urbano-Marquez A lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies. J Neurol Sci 1996, 138:42-48.
76. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, Giralt M, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006, 50:3824-3832.
77. Lonergan JT, Barber RE, Mathews WC Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003, 17:2495-2499.
78. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
79. Birkus G, Hitchcock MJ, Cihlar T Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46:716-723.
80. Wensing AM, van Maarseveen NM, Nijhuis M Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 2010, 85:59-74.
81. Badley AD In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 2005, 12(Suppl 1):924-931.
82. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MS HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol 1999, 2:261-269.
83. Sloand EM, Young NS, Sato T, Kim S, Maciejewski JP Inhibition of interleukin-1beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp Hematol 1998, 26:1093-1099.
84. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001, 98:1078-1085.
85. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999, 94:1021-1027.
86. Chavan S, Kodoth S, Pahwa R, Pahwa S The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 2001, 98:383-389.
87. Ghibelli L, Mengoni F, Lichtner M, Coppola S, De Nicola M, Bergamaschi A, Mastroianni C, et al. Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem Pharmacol 2003, 66:1505-1512.
88. Cuerrier D, Nie Z, Badley AD, Davies PL Ritonavir does not inhibit calpain in vitro. Biochem Biophys Res Commun 2005, 327:208-211.
89. Vanderklish PW, Bahr BA The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol 2000, 81:323-339.
90. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R, Malorni W Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol 2003, 170:6006-6015.
91. Matarrese P, Tinari A, Gambardella L, Mormone E, Narilli P, Pierdominici M, Cauda R, et al. HIV protease inhibitors prevent mitochondrial hyperpolarization and redox imbalance and decrease endogenous uncoupler protein-2 expression in gp 120-activated human T lymphocytes. Antivir Ther 2005, 10(Suppl 2):M29-M45.
92. Miro O, Villarroya J, Garrabou G, Lopez S, Rodriguez de la Concepcion M, Pedrol E, Martinez E, et al. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis. Antivir Ther 2005, 10:945-951.
93. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, Nakao S, Ito Y, et al. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest 2008, 118:2025-2038.
94. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
95. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using Interna tional Diabetes Foun dation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. Diabetes Care 2007, 30:455-1119. Erratum in:.
96. Barbaro G, Iacobellis G Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009, 9:37-42.
97. Grinspoon S, Carr A Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
98. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
99. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
100. Carr A, Miller J, Law M, Cooper DA A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
101. Carr A, Cooper DA Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430.
102. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003, 32:370-374.
103. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C, Esposito R, et al. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003, 8:315-321.
104. Calmy A, Hirschel B, Cooper DA, Carr A A new era of antiretroviral drug toxicity. Antivir Ther 2009, 14:165-179.
105. Ladha JS, Tripathy MK, Mitra D Mitochondrial complex I activity is impaired during HIV-1-induced T-cell apoptosis. Cell Death Differ 2005, 12:1417-1428.
106. Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med 2006, 7:53-58.
107. Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, Iwamoto A Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003, 70:497-505.
108. Prakash O, Teng S, Ali M, Zhu X, Coleman R, Dabdoub RA, Chambers R, et al. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice. Arch Biochem Biophys 1997, 343:173-180.
109. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992, 176:1099-1106.
110. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340.
111. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F Programmed death of T cells in HIV-1 infection. Science 1992, 257:217-219.
112. Lopes MF, da Veiga VF, Santos AR, Fonseca ME, DosReis GA Activation-induced CD4 + T cell death by apoptosis in experimental Chagas' disease. J Immunol 1995, 154:744-752.
113. Franceschi C, Franceschini MG, Boschini A, Trenti T, Nuzzo C, Castellani G, Smacchia C, et al. Phenotypic characteristics and tendency to apoptosis of peripheral blood mononuclear cells from HIV + long term non progressors. Cell Death Differ 1997, 4:815-823.
114. Cossarizza A, Mussini C, Mongiardo N, Borghi V, Sabbatini A, De Rienzo B, Franceschi C Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS 1997, 11:19-26.
115. Ohnimus H, Heinkelein M, Jassoy C Apoptotic cell death upon contact of CD4 + T lymphocytes with HIV glycoprotein-expressing cells is mediated by caspases but bypasses CD95 (Fas/Apo-1) and TNF receptor 1. J Immunol 1997, 159:5246-5252.
116. Kaul M, Lipton SA Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96:8212-8216.
117. Ferri KF, Jacotot E, Blanco J, Este JA, Zamzami N, Susin SA, Xie Z, et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases. J Exp Med 2000, 192:1081-1092.
118. Hashimoto F, Oyaizu N, Kalyanaraman VS, Pahwa S Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Blood 1997, 90:745-753.
119. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, et al. Apoptosis of CD8 + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395:189-194.
120. Berndt C, Mopps B, Angermuller S, Gierschik P, Krammer PH CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl Acad Sci USA 1998, 95:12556-12561.
121. Fermin CD, Garry RF Membrane alterations linked to early interactions of HIV with the cell surface. Virology 1992, 191:941-946.
122. Garg H, Blumenthal R HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006, 79:351-362.
123. Cossarizza A Apoptosis and HIV infection: about molecules and genes. Curr Pharm Des 2008, 14:237-244.
124. Xu XN, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, Mongkolsapay J, et al. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med 1999, 189:1489-1496.
125. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001, 410:834-838.
126. Rasola A, Gramaglia D, Boccaccio C, Comoglio PM Apoptosis enhancement by the HIV-1 Nef protein. J Immunol 2001, 166:81-88.
127. Sastry KJ, Marin MC, Nehete PN, McConnell K, el-Naggar AK, McDonnell TJ Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene 1996, 13:487-493.
128. Bartz SR, Emerman M Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 1999, 73:1956-1963.
129. Gibellini D, Re MC, Ponti C, Vitone F, Bon I, Fabbri G, Grazia Di Iasio M, et al. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity. J Cell Physiol 2005, 203:547-556.
130. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268:429-431.
131. Creaven M, Hans F, Mutskov V, Col E, Caron C, Dimitrov S, Khochbin S Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat. Biochemistry 1999, 38:8826-8830.
132. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995, 14:546-554.
133. Connor RI, Chen BK, Choe S, Landau NR Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
134. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol 1992, 66:3925-3931.
135. Levy DN, Refaeli Y, Weiner DB Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 1995, 69:1243-1252.
136. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, Weiner DB HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002, 277:37820-37831.
137. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001, 193:509-519.
138. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000, 191:33-46.